drugset / Trial / NCT04457284
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will test whether the combination of cisplatin, nivolumab, and temozolomide is an effective treatment for in people with advanced and/or metastatic colorectal cancer that is mismatch repair-proficient (MMR-proficient). The researchers will also look at how safe the study drug combination is in participants.
Timeline
- Start
- 2020-11-18
- Primary completion
- 2026-06-17
- Completion
- 2026-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |